Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Trial Profile

A Phase 1b, Randomized, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) and Interferon Gamma (IFN-gamma) for Recurrent Glioblastoma or Gliosarcoma (TARGET-I)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 06 Nov 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tasadenoturev (Primary) ; Interferon gamma
  • Indications Glioblastoma; Gliosarcoma
  • Focus Therapeutic Use
  • Acronyms TARGET-I
  • Sponsors DNAtrix

Most Recent Events

  • 23 Sep 2023 Results assessing the impact of neutralizing antibodies developed in patients during a phase 1 clinical trial of Delta-24-RGD for the treatment of recurrent malignant gliomas, presented at the CRI-ENCI-AACR: 7th Annual International Cancer, Immunotherapy Conference.
  • 12 Jul 2018 Status changed from active, no longer recruiting to completed.
  • 30 Jan 2018 Planned primary completion date changed from 1 Aug 2017 to 15 Mar 2018.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top